Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

← catalyst calendar

NCT06736509 · results posted

Sponsored by Axsome Therapeutics, Inc. (industry) · AXSM — their whole pipeline →.

Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
139actual
Sites
22
Countries
Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Study AXS-05-AD-305 was terminated due to completion of overall program objectives.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-11-21actualWhen the study began enrolling
Primary completion2025-02-17actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-04-25actualThe whole study's end, after follow-up
First posted2024-12-16actualWhen this record first appeared on the registry
Results posted2026-06-25actualWhen the sponsor posted results to the registry
Record updated2026-06-25actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Alzheimer Disease
  • Agitation, Psychomotor

Intervention

  • Drug: AXS-05 (dextromethorphan-bupropion)

Primary outcome

what the primary-completion date above is the date OF
Long-Term Safety
measured Up to 25 weeks

Posted documents

hosted by the registry — we link, never re-serve
Study Protocol and Statistical Analysis Planposted 2024-10-18 · 399 KB · Prot_SAP_000.pdf

Permalink · AXSM's whole pipeline · Catalyst calendar · Every registered study · What changed